Until law, GLP-1 drugs were used to treat diabetes, obesity and even the recent evidences suggest that it could as well be used to treat chronic kidney problems. There is yet another research, published in JAMA Psychiatry on February 25, titled Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial that explores if GLP-1 receptor agonist semaglutide reduce alcohol consumption and cravings in adults with alcohol use disorder.

What Do Studies Say?

The research was conducted over a period of 9 weeks, where in the randomized clinical trial, the participants who were administered semaglutide, it led to reductions in some but not all measures of weekly consumptions. It also reduced weekly alcohol and craving related to placebo, and also led to a greater relative reduction in cigarettes per day.

The research also found that weekly injections of semaglutide, which is the active ingredient in weight loss drugs like Wegovy also helped reduce cravings in people with alcohol use disorder.

The lead author Christian Hendershot said that these findings will help in developing new approaches to treat alcoholism. "Two drugs currently approved to reduce alcohol consumption aren't widely used. The popularity of Ozempic and other GLP-1 receptor agonists increases the chances of broad adoption of these treatments for alcohol use disorder," said Hendershot in news release by the University of Southern California's Institute for Addiction Research, where he is the director.

The study is government-funded research and was funded by the National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health.

How Was The Study Conducted?

The study was small, and took in account for only 48 adults over two months, thus experts say that it is not yet clear how safe these drugs are for people who do not need to lose weight. Though the results do add up with the evidence form animal studies on drugs like Ozempic and Wegovy on how it helps manage cravings, not just for food, but also for tobacco and alcohol. Scientists are also studying these drugs on smokers, people with opioid addiction and cocaine users.

Co-author Dr Klara Klein of the University of North Carolina at Chapel Hill who treats people with obesity and diabetes said, "This is such promising data. And we need more of it. We frequently will hear that once people start these medications that their desire to drink is very reduced, if not completely abolished."

Why Does It Work So Well Against Alcoholism?

The GLP-1 receptor agonists work by mimicking hormones GLP-1 in the gut and brain that regulates appetite and feelings of fullness. This response is what helps one lose weight, and what helps one curb their craving for alcohol. These drugs that mimic the functioning of your brain, which is responsible to tell your body when to stop consuming, are the same hormones that tell your body about other kinds of consumptions, including alcohol. Therefore by consuming the weight loss drugs one can treat alcohol use disorder.

However, the researchers have pointed out on the limited data on the research and have suggested to continue using the three approved drugs by the National Institute on Alcohol Abuse and Alcoholism and Substance Abuse and Mental Health Services Administration, namely, Disulfiram, Naltrexone, and Acamprosate to treat alcohol use disorder until large studies confirm these findings.

Scientists have identified a new H1N1 mutation, G155E, in US flu samples, raising questions about immunity and vaccine protection as the flu season begins early.

Early laboratory findings suggest the mutation may make some H1N1 strains harder for existing antibodies to recognize. However, the vaccine’s effectiveness specifically against G155E remains uncertain, and there is no evidence yet that the mutation makes the flu shot ineffective.

H1N1 Becomes The Dominant Flu Strain In US

According to the US Centers for Disease Control and Prevention’s (CDC) October 2 report, 53 of 55 influenza A samples undergoing subtyping were H1N1, while two were H3N2. No influenza B viruses were reported in this group.

Researchers at the University of Washington identified G155E in 13 of 17 sequenced H1N1 samples collected from hospitals and clinics in the Seattle area.

Could G155E Affect Flu Shot Effectiveness?

Also read: Flu 2026: Symptoms To Watch For As New Season Begins

The 2026-2027 flu vaccines approved by the US Food and Drug Administration target H1N1, H3N2 and an influenza B virus.

Dr. Jennifer Duchon, a pediatric infectious disease expert at Mount Sinai Children’s Hospital, told Reuters that younger people may have had limited exposure to this year’s H1N1 strain.

“What people are a bit worried about is that the H1N1 strain this year hasn't been seen by a lot of younger folk, so it may be more severe in them,” she said.

However, this concern does not establish that G155E causes more severe disease. Flu vaccine effectiveness varies by season and depends partly on how well vaccine strains match circulating viruses.

Scott Hensley, a microbiologist at the University of Pennsylvania, told Reuters that two of this season’s three vaccine components appear well matched to circulating strains. He also recommended getting vaccinated early.

The American Medical Association also recommends annual flu vaccination for people aged six months and older, unless they have a medical reason not to receive it.

G155E: Who Could Be More Vulnerable?

Read More: Flu Vaccine: Why October Is A Good Time To Get Your Family Vaccinated

Antibody studies suggest that people exposed to influenza last year may have antibodies that recognize the new mutation less effectively, particularly among teenagers and young adults.

Researchers at the Fred Hutchinson Cancer Center, including virologist Jesse Bloom, examined antibody responses to influenza A strains carrying mutations such as G155E.

In a preprint posted on bioRxiv, researchers tested antibodies from 260 people in Australia and the US against 148 influenza A strains that circulated through mid-2026. Some G155E-carrying strains were less readily recognized by antibodies, particularly those from younger people.

The researchers suggested that limited previous exposure to similar H1N1 variants could help explain this difference. However, laboratory findings alone cannot establish how likely people are to become infected or develop severe illness.

Should You Worry About G155E?

The mutation warrants monitoring, but current evidence does not establish that it makes the flu shot ineffective. How well this season’s vaccine protects against G155E remains uncertain.

Annual flu vaccination remains an important preventive measure, particularly for people at higher risk of complications. Regular hand hygiene and other basic precautions can also help reduce the spread of infections.

Emmy-winning American actor Christina Applegate has in a shocking news revealed that she does not have multiple sclerosis (MS), despite continuing to experience debilitating symptoms since her 2021 diagnosis.

Applegate, 54, shared the news in an episode of her podcast MeSsy, co-hosted with fellow actor Jamie-Lynn Sigler and posted to YouTube on Tuesday.

“I’m back at square one – that I don’t know what’s going on with me,” she said through tears.

Applegate had gradually withdrawn from public life after her MS diagnosis in 2021, as she navigated the physical and emotional toll of the condition.

She has also become an advocate for MS awareness and chronicled her struggles in an emotional memoir published in March.

Christina Applegate Recalls Learning About Her Misdiagnosis

Also read: Why Multiple Sclerosis Increases Emotional Burden Among Women

Applegate recalled a visit to her doctor when she was told she did not have MS.

“She came into my room and said, ‘Congratulations, you don’t have MS,’” Applegate recalled through tears. “I was, like, not happy at all. Everybody else was so happy.”

Despite the news, Applegate said her symptoms have not improved.

“I haven’t gotten better. I still have to use wheelchairs when I go to the doctor’s office. I can’t walk from the car to the room. I’m still in this. Nothing magical happened when she said, ‘You don’t have MS.’ Nothing magical happened.”

Applegate also described feeling confused about her condition and the uncertainty surrounding her symptoms.

“It’s weird because I feel like I let everybody down. It’s this weird feeling of like I became this, you and I, the poster children for MS. Everything that I was doing, I had a fucking reason as to why my day sucked every day.

“And now I don’t have a reason. It’s very unnerving and it’s really confusing for me.”

What Is Multiple Sclerosis?

Read More: Selena Gomez Says Vaping Changed Her Voice: How E-Cigarettes Affect Vocal Cords

According to the National Institute of Neurological Disorders and Stroke, multiple sclerosis is a chronic neurological condition that affects the central nervous system, including the brain, spinal cord and optic nerves.

MS is also an immune-mediated disease in which the immune system attacks myelin, the protective sheath surrounding nerve fibers. Damage to myelin can disrupt nerve signals, causing symptoms that vary from person to person.

These may include muscle weakness, fatigue, numbness, coordination problems, vision changes and memory difficulties.

MS is commonly diagnosed between the ages of 20 and 40, although it can develop earlier or later. There is no cure, but treatments can help manage symptoms and slow disease progression. Some people experience relapses with periods of improvement, while others develop progressively worsening disability.

Why Is Multiple Sclerosis Hard To Diagnose?

Dr. Marwa Kaisey, an associate professor in the Department of Neurology at Cedars-Sinai Medical Center, joined Applegate and Sigler on the podcast to discuss MS misdiagnosis.

Kaisey said misdiagnoses are “fairly common” because there is no single test that can definitively confirm or rule out MS.

“We don’t have one single test for MS. It’s not like we have something like a pregnancy test that says, ‘Yes. You have it.’ ‘No. You don’t.’ It’s a list of criteria.”

Kaisey said nearly 20% of people diagnosed with MS may not actually have the disease, People.com reported.

“Almost one in five of these people who’d been told they had MS, some for decades, didn’t actually have it. And a majority of them were on medication to treat their MS,” she said.

MS diagnosis typically involves assessing symptoms, a neurological examination, magnetic resonance imaging (MRI) and, when appropriate, additional tests to rule out other conditions.

Because several disorders can cause similar symptoms, clinicians must evaluate the findings against established diagnostic criteria.

The UK is seeing a rise in COVID-19 infections ahead of winter, with the XFG variant, also known as Stratus, among the circulating strains.

Cases, hospital admissions and deaths have increased, while flu and respiratory syncytial virus (RSV) are also concerns heading into the colder months.

COVID Cases And Deaths Rise In UK

Latest UK Health Security Agency (UKHSA) data show around 2.46 COVID-19 hospital admissions per 100,000 people each week.

The UK recorded 3,942 confirmed cases in October so far, compared with 4,589 in September and 1,374 in August.

People aged 85 and older remain the most vulnerable, with almost 27 hospital admissions per 100,000 people, more than 10 times the national average. Around 13.5% of this age group tested positive, compared with 8.8% across all age groups.

COVID-19 deaths rose 46.4%, from 28 to 41, in the week ending October 2. Cases increased 13.5% in the week to October 7, according to UKHSA data.

Unusual COVID Symptoms: Red And Itchy Eyes

Also read: XFG Variant In Spain: COVID-19 Cases Rise Amid Respiratory Infection Surge

A persistent cough, fever and sore throat are familiar COVID-19 symptoms. However, eye irritation and conjunctivitis may also signal infection, pharmacist Noel Wicks told The Mirror.

“The COVID-19 virus can enter the body through our eyes where it may cause symptoms.”

Wicks said conjunctivitis, which causes red, irritated and sometimes sticky eyes, can occur even without other COVID-19 symptoms.

“Clinical studies have demonstrated that conjunctivitis (red eye) is present in people who test positive for coronavirus, with rates of conjunctivitis ranging from 2% to over 14%, even if people don’t have any other COVID symptoms. In fact, conjunctivitis can be the first and/or the only symptom of COVID,” he said.

Research involving 6,308 people found that approximately 11% of COVID-19 patients experienced eye symptoms. These included conjunctivitis, dryness, redness, watering and itching.

Signs Of COVID-Related Conjunctivitis

Read More: XFG COVID Variant: What India Should Watch As Cases Rise In UK And France

According to Wicks, symptoms may include:

• Pink or red whites of the eyes
• Sore or inflamed eyelids
• Gritty, itchy eyes
• White or yellow discharge

“These symptoms need to be tackled very quickly,” he said.

There is no established evidence that XFG causes eye symptoms more frequently than other COVID-19 variants. Allergies, bacterial infections and other viruses can also cause eye irritation, so these symptoms alone cannot confirm COVID-19.

How To Manage Eye Irritation

Wicks recommends gently cleaning the eyes, avoiding rubbing them and temporarily stopping contact lens use and eye makeup until symptoms improve.

“Make sure to keep your eyes clean by washing them gently with a clean flannel to remove any crusts. Don’t rub your eyes as this can transfer infection from your hands to your eyes. Remove contact lenses and don’t wear eye makeup until the infection is better,” he advised.

Persistent irritation warrants advice from a healthcare professional. Eye pain, sensitivity to light or changes in vision require urgent medical assessment.

What Is The COVID XFG Variant?

XFG, also known as Stratus, is a recombinant Omicron lineage formed when two Omicron sub-lineages combined. The World Health Organization classified it as a variant under monitoring in 2025 because of its growth advantage.

Although XFG carries mutations in its spike protein, studies suggest its ability to evade immunity differs only slightly from that of other JN.1 descendants.

There is no evidence that XFG causes more severe illness than other circulating Omicron variants. However, increased transmission can still raise hospital admissions by increasing the overall number of infections.